Research on the Mechanism of Drug-drug Interaction Between Salvianolate Injection and Aspirin Based on the Metabolic Enzyme and PK-PD Model: Study Protocol for a PK-PD Trial

Overview

Journal Trials

Publisher Biomed Central

Specialties General Medicine
Pharmacology

Date 2018 Sep 16

PMID 30217228

Citations 1

Authors

Wantong Zhang

Baochen Zhu

Weiyi Cao

Rui Li

Shuge Wang

Rui Gao

Affiliations

Soon will be listed here.

Abstract

Background: Coronary heart disease (CHD) is a common cardiovascular disease accounting for 10-20% mortality by heart disease worldwide. The gold standard treatment to manage CHD is aspirin, which may prevent myocardial infarction and sudden death; however, long-term use of aspirin may increase its side effects. Currently, more and more clinicians are exploring different approaches to use the right combination of medicine to enhance the efficacy and reduce side effects. Salvianolate can significantly inhibit the aggregation and activation of platelets in patients with CHD; however, its optimum combination with western medicine is not established or supported by clinical trial results.

Methods/design: This trial is a prospectively planned, open-labeled, parallel-grouped, single-centered clinical trial with aggregated pharmacodynamics-pharmacokinetics (PK-PD) data. All treatment courses will last for 10 days and blood sample will be acquired before administration on days 8, 9, and 10, and after administration at 5 min, 15 min, 30 min, 45 min, 1 h, 2 h, 4 h, 8 h, 12 h, and 24 h on day 10. This trial uses PK-PD modeling to provide a description of the concentration-effect relationship and an estimate of pharmacological potency of the medicine. The primary outcome will be changes in aspirin esterase and catechol-o-methyltransferase (COMT) activity at different blood concentrations to determine the PK-PD characteristics of the combination of salvianolate and aspirin, followed by analysis of the correlation between exposure level and pharmacodynamic index of the medicines.

Discussion: This trial will aim to evaluate the relationship between changes in the pharmacokinetics and therapeutic effect index in the combined use of salvianolate and aspirin. It also discusses the possible mechanism of medicine combination in the treatment for CHD and provides an experimental basis for a clinically rational medicine combination.

Trial Registration: ClinicalTrials.gov, NCT03306550 . Registered on 9 October 2017. ClinicalTrials.gov https://register.clinicaltrials.gov/prs/app/action/SelectProtocol?sid=S0007D8H&selectaction=Edit&uid=U0003QY8&ts=2&cx=oiuc9g.

Citing Articles

Combination of Xuesaitong and Aspirin Based on the Antiplatelet Effect and Gastrointestinal Injury: Study Protocol for a Randomized Controlled Noninferiority Trial.

Zhu B, Xue C, Lang R, Weng W, Wang X, Lei Z Evid Based Complement Alternat Med. 2021; 2021:5552506.

PMID: 34335822 PMC: 8294960. DOI: 10.1155/2021/5552506.

References

Tachjian A, Maria V, Jahangir A . Use of herbal products and potential interactions in patients with cardiovascular diseases. J Am Coll Cardiol. 2010; 55(6):515-25. PMC: 2831618. DOI: 10.1016/j.jacc.2009.07.074. View

Crow J, Borazjani A, Potter P, Ross M . Hydrolysis of pyrethroids by human and rat tissues: examination of intestinal, liver and serum carboxylesterases. Toxicol Appl Pharmacol. 2007; 221(1):1-12. PMC: 2692260. DOI: 10.1016/j.taap.2007.03.002. View

Fang C, Ren X, Zhou H, Gong Z, Shen L, Bai J . Effects of eNOS rs1799983 and ACE rs4646994 polymorphisms on the therapeutic efficacy of salvianolate injection in Chinese patients with coronary heart disease. Clin Exp Pharmacol Physiol. 2014; 41(8):558-64. DOI: 10.1111/1440-1681.12257. View

Liu L, Li J, Zhang Y, Zhang S, Ye J, Wen Z . Salvianolic acid B inhibits platelets as a P2Y12 antagonist and PDE inhibitor: evidence from clinic to laboratory. Thromb Res. 2014; 134(4):866-76. DOI: 10.1016/j.thromres.2014.07.019. View

Bahar F, Imai T . Aspirin hydrolysis in human and experimental animal plasma and the effect of metal cations on hydrolase activities. Drug Metab Dispos. 2013; 41(7):1450-6. DOI: 10.1124/dmd.113.051805. View

Chang Y, Zhang H, Xie Y, Zeng X, Hu J, Zhuang Y . [Analysis of salvianolate injection combined with usual drugs in treatment of coronary heart disease in real world]. Zhongguo Zhong Yao Za Zhi. 2014; 38(18):3186-9. View

EISENBERG D, Davis R, Ettner S, Appel S, Wilkey S, Van Rompay M . Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA. 1998; 280(18):1569-75. DOI: 10.1001/jama.280.18.1569. View

Barnes J, Mills S, Abbot N, Willoughby M, Ernst E . Different standards for reporting ADRs to herbal remedies and conventional OTC medicines: face-to-face interviews with 515 users of herbal remedies. Br J Clin Pharmacol. 1998; 45(5):496-500. PMC: 1873549. DOI: 10.1046/j.1365-2125.1998.00715.x. View

Backman J, Yerges-Armstrong L, Horenstein R, Newcomer S, Shaub S, Morrisey M . Prospective Evaluation of Genetic Variation in Platelet Endothelial Aggregation Receptor 1 Reveals Aspirin-Dependent Effects on Platelet Aggregation Pathways. Clin Transl Sci. 2017; 10(2):102-109. PMC: 5355965. DOI: 10.1111/cts.12438. View

10.

He Q, Wang S, Liu X, Guo H, Yang H, Zhang L . Salvianolate lyophilized injection promotes post-stroke functional recovery via the activation of VEGF and BDNF-TrkB-CREB signaling pathway. Int J Clin Exp Med. 2015; 8(1):108-22. PMC: 4358435. View

11.

Lynch T, Price A . The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007; 76(3):391-6. View

12.

Guthrie R . Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events. Adv Ther. 2011; 28(6):473-82. DOI: 10.1007/s12325-011-0026-0. View

13.

Mukherjee P, Ponnusankar S, Pandit S, Hazam P, Ahmmed M, Mukherjee K . Botanicals as medicinal food and their effects on drug metabolizing enzymes. Food Chem Toxicol. 2011; 49(12):3142-53. DOI: 10.1016/j.fct.2011.09.015. View

14.

Li Y, Wang L, Xie Y . [Mechanism of Salvianolate injection combined with aspirin in treatment of stable angina pectoris based on biomolecules network]. Zhongguo Zhong Yao Za Zhi. 2017; 41(24):4521-4532. DOI: 10.4268/cjcmm20162408. View

15.

Hasanaj Q, Wilson B, Little J, Montazeri Z, Carroll J . Family history: impact on coronary heart disease risk assessment beyond guideline-defined factors. Public Health Genomics. 2013; 16(5):208-14. DOI: 10.1159/000353460. View

16.

Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A . Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res. 1980; 17(3-4):317-27. DOI: 10.1016/0049-3848(80)90066-3. View

17.

Chen Z, Xie Y, Liao X, Wang G . [Systematic review on safety of Salvianolate injection]. Zhongguo Zhong Yao Za Zhi. 2017; 41(19):3686-3695. DOI: 10.4268/cjcmm20161931. View

18.

Hamberg M, Svensson J, Samuelsson B . Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A. 1975; 72(8):2994-8. PMC: 432905. DOI: 10.1073/pnas.72.8.2994. View

19.

Watson K, Gorczyca W, Umland J, Zhang Y, Chen X, Sun S . Pharmacokinetic-pharmacodynamic modelling of the effect of Moxifloxacin on QTc prolongation in telemetered cynomolgus monkeys. J Pharmacol Toxicol Methods. 2011; 63(3):304-13. DOI: 10.1016/j.vascn.2011.03.002. View

20.

Piotrovsky V . Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation. AAPS J. 2005; 7(3):E609-24. PMC: 2751265. DOI: 10.1208/aapsj070363. View